Lipe & Dalton Exact Sciences Corp Transaction History

Lipe & Dalton

$186 Million
Q2 2024

A detailed history of Lipe & Dalton transactions in Exact Sciences Corp stock. As of the latest transaction made, Lipe & Dalton holds 9,020 shares of EXAS stock, worth $635,459. This represents 0.2% of its overall portfolio holdings.

Number of Shares

9,020

Previous 7,270 24.07%

Holding current value

$635,459

Previous $502,000 24.1%

% of portfolio

0.2%

Previous 0.26%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$41.33 - $74.26 $72,327 - $129,955	1,750 Added 24.07%	9,020 $381,000
Q1 2024 May 07, 2024	BUY	$56.27 - $73.77 $101,286 - $132,786	1,800 Added 32.91%	7,270 $502,000
Q4 2023 Jan 30, 2024	BUY	$59.06 - $75.72 $23,624 - $30,288	400 Added 7.89%	5,470 $405,000
Q3 2023 Nov 03, 2023	BUY	$65.94 - $99.04 $36,267 - $54,472	550 Added 12.17%	5,070 $346,000
Q2 2023 Jul 26, 2023	BUY	$62.68 - $95.05 $47,010 - $71,287	750 Added 19.89%	4,520 $424,000
Q1 2023 May 02, 2023	SELL	$47.19 - $70.77 $23,595 - $35,385	-500 Reduced 11.71%	3,770 $256,000
Q4 2022 Feb 03, 2023	BUY	$30.35 - $53.15 $3,035 - $5,315	100 Added 2.4%	4,270 $211,000
Q3 2022 Nov 07, 2022	BUY	$31.97 - $49.37 $15,985 - $24,685	500 Added 13.62%	4,170 $135,000
Q2 2022 Aug 01, 2022	BUY	$35.61 - $76.23 $130,688 - $279,764	3,670 New	3,670 $145,000
Q2 2020 Aug 07, 2020	SELL	$55.75 - $92.75 $360,702 - $600,092	-6,470 Closed	0 $0
Q1 2020 May 01, 2020	BUY	$37.9 - $104.44 $245,213 - $675,726	6,470 New	6,470 $375,000

Others Institutions Holding EXAS

# of Institutions

637

Shares Held

166M

Call Options Held

1.93M

Put Options Held

1.23M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12.5B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lipe & Dalton, based on Form 13F filings with the SEC.

News

Stay updated on Lipe & Dalton with notifications on news.

Account